ARQL Shares Outstanding History



Below is a table of the ARQL shares outstanding history going back to 2/16/2010:

Date ARQL Shares Outstanding
2/16/201044.73M
4/28/201044.79M
7/27/201044.89M
11/1/201044.95M
2/16/201153.10M
4/27/201153.38M
7/27/201153.73M
10/26/201153.77M
2/16/201253.95M
3/23/201253.97M
4/26/201262.20M
7/24/201262.28M
10/24/201262.34M
2/25/201362.86M
4/29/201362.62M
7/22/201362.72M
10/28/201362.70M
2/25/201462.86M
4/23/201462.72M
7/23/201462.77M
10/27/201462.77M
2/24/201562.81M
4/22/201562.82M
7/22/201562.88M
10/22/201562.89M
2/17/201662.93M
4/20/201671.06M
7/20/201671.11M
10/24/201671.12M
2/24/201771.14M
4/20/201771.15M
7/20/201771.17M
10/25/201787.11M
2/20/201887.11M
4/20/201887.13M
7/19/2018108.82M
10/17/2018108.99M
2/20/2019109.00M
4/17/2019109.31M
7/24/2019120.26M
10/16/2019120.73M

Also see: ARQL Market Cap History
ARQL YTD Return
ARQL Historical Shares Outstanding:
+10.82% CAGR
ARQL Historical Shares Outstanding: +10.82% CAGR

Mouse over chart for data details
2/16/2010 ...10/16/2019
ArQule is a biopharmaceutical company engaged in the research and development of therapeutics to treat cancers and rare diseases. Co.'s clinical pipeline includes: ARQ 531, which is a reversible dual inhibitor of both wild type and C481S-mutant Bruton's tyrosine kinase for B-cell malignancies refractory to other therapeutic options; Miransertib, which is a selective inhibitor of protein kinase B (AKT) in combination with the hormonal therapy, anastrozole; ARQ 751, which is a selective inhibitor of AKT for solid tumors harboring AKT, phosphoinositide 3-kinase or phosphatase and tensin homolog (PTEN) mutations or that are PTEN null; and Derazantinib, which is a multi-kinase inhibitor. We show 41 historical shares outstanding datapoints in our coverage of ARQL's shares outstanding history.

Understanding the changing numbers of ARQL shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like ARQL versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching ARQL by allowing them to research ARQL shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree ARQL Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
ArQule (ARQL) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

ARQT Shares Outstanding History
ARTL Shares Outstanding History
ARVN Shares Outstanding History
ARWR Shares Outstanding History
ASMB Shares Outstanding History
ASPI Shares Outstanding History
ASRT Shares Outstanding History
ASTH Shares Outstanding History
ATEC Shares Outstanding History
ATHA Shares Outstanding History
More Healthcare companies »

 

ARQL Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2024, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 9.5%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 9.5%.